BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27620278)

  • 1. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
    Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
    Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
    Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
    Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.
    Maliszewska A; Leandro-Garcia LJ; Castelblanco E; Macià A; de Cubas A; Goméz-López G; Inglada-Pérez L; Álvarez-Escolá C; De la Vega L; Letón R; Gómez-Graña Á; Landa I; Cascón A; Rodríguez-Antona C; Borrego S; Zane M; Schiavi F; Merante-Boschin I; Pelizzo MR; Pisano DG; Opocher G; Matias-Guiu X; Encinas M; Robledo M
    Am J Pathol; 2013 Feb; 182(2):350-62. PubMed ID: 23201134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
    Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
    Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
    Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
    Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
    Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
    Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
    [No Abstract]   [Full Text] [Related]  

  • 11. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
    Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
    Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
    Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
    Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.
    Frisk T; Zedenius J; Lundberg J; Wallin G; Kytölä S; Larsson C
    Int J Oncol; 2001 Jun; 18(6):1219-25. PubMed ID: 11351254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR activation in medullary thyroid carcinoma with RAS mutation.
    Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
    Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
    Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
    Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
    [No Abstract]   [Full Text] [Related]  

  • 20. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.